The WATCHMAN FLX device showed superior safety with 8.5% major bleeding at 36 months, compared to 18.1% with oral ...
Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.
Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...
21h
In a report released on November 15, David Rescott from Robert W. Baird maintained a Buy rating on Boston Scientific (BSX – Research Report), ...
The Cottage Heart & Vascular Center’s structural heart team at Santa Barbara Cottage Hospital (SBCH) recently performed their ...
Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.
Abbott Park, Illinois Wednesday, November 20, 2024, 13:00 Hrs [IST] ...
Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...
(Courtesy photo) The Cottage Heart & Vascular Center’s structural heart team at Santa Barbara Cottage Hospital (SBCH) recently performed their 1,000th WATCHMAN device procedure, a minimally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback